TABLE 3.

Reactivation study

Expt	Site	Experimental groupa	No. of CFUb
			Day 21	Day 42	Day 52	Day 63
1	Lung	Drug treated	4.98 ± 0.07	4.98 ± 0.30		5.28 ± 0.48
		Drug treated + DNA	5.12 ± 0.11	4.88 ± 0.10		5.08 ± 0.39
		Drug treated + vector	5.41 ± 0.44	5.24 ± 0.13		5.10 ± 0.39
	Spleen	Drug treated	3.87 ± 0.25	4.25 ± 0.49		4.15 ± 0.75
		Drug treated + DNA	3.37 ± 0.22 (−0.50)c	3.88 ± 0.30		3.90 ± 0.45
		Drug treated + vector	4.28 ± 0.20	4.38 ± 0.47		4.26 ± 0.49
2	Lung	Drug treated	5.45 ± 0.35		5.36 ± 0.30
		Drug treated + DNA	5.13 ± 0.23		5.07 ± 0.24
	Spleen	Drug treated	5.63 ± 0.21		4.87 ± 0.28
		Drug treated + DNA	5.32 ± 0.16		4.89 ± 0.37

^aDrug treated, H37Rv primary infection followed by INH and RIF chemotherapy; drug treated + DNA, primary infection followed by chemotherapy and DNA vaccination; drug treated + vector, primary infection followed by chemotherapy and injection of the vector control.

^bMean CFU ± standard deviation; the number in parentheses represents a log₁₀ reduction in CFU in experimental mice relative to that in naïve mice.

^cDrug-treated + DNA group is significantly less than drug-treated-only group (P < 0.05).